Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
AZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.24 - $87.68
Previous CloseN/A
Volume1.80M
Average Volume (3M)4.91M
Market Cap
$227.80B
Enterprise Value$243.71B
Total Cash (Recent Filing)$7.11B
Total Debt (Recent Filing)$32.84B
Price to Earnings (P/E)27.4
Beta0.29
Next Earnings
Nov 06, 2025EPS Estimate
1.14Last Dividend Ex-Date
Aug 08, 2025Dividend Yield2.11%
Share Statistics
EPS (TTM)1.08
Shares Outstanding3,101,365,200
10 Day Avg. Volume7,028,422
30 Day Avg. Volume4,906,909
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)4.98
Price to Sales (P/S)3.76
P/FCF Ratio27.92
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda18.07
Forecast
1Y Price Target
$90.75Price Target Upside22.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceThe company reported Total Product Sales of $13.795bn, above consensus estimates, driven by the oncology segment.
Product DevelopmentBaxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo.
Regulatory ApprovalsRegulatory filings accepted for multiple products in the US, EU, and Japan.
Bears Say
Clinical TrialsThe clinical program evaluating anselamimab did not achieve statistical significance in the overall population for the primary endpoint.
Product Trial DiscontinuationThe discontinuation of the CAPItello-280 Ph 3 trial evaluating Truqap in patients with metastatic castration-resistant prostate cancer was announced.
Sales PerformancePerformance across non-oncology products were mixed, with some products below consensus.
AstraZeneca News
AZN FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was $61.24 and its highest was $87.67 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Astrazeneca Plc’s market cap is $227.80B.
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Nov 06, 2025 which is in 86 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Jul 29, 2025. The company reported $1.085 earnings per share for the quarter, beating the consensus estimate of $1.074 by $0.011.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of $0.515 which represents an annual dividend yield of 2.11%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is 1.14.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,101,365,200 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of $1.085 in its last earnings report, beating expectations of $1.074. Following the earnings report the stock price went up 3%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Currently, no hedge funds are holding shares in AZN
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.75 (22.52% Upside)
$90.75 (22.52% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 8.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.70%
12-Months-Change
Fundamentals
Return on Equity
19.76%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Astrazeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Company Deck
AZN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AstraZeneca's earnings call presented a strong performance with significant revenue and EPS growth, driven by robust demand across oncology and biopharmaceuticals. The company achieved numerous regulatory approvals and positive clinical trial results, indicating a successful pipeline and future growth potential. However, challenges such as the impact of Medicare Part D redesign, Soliris biosimilar competition, and growth rate issues in China were noted. Overall, the positive highlights outweigh the challenges, suggesting a promising outlook.View all AZN earnings summariesAZN Stock 12 Month Forecast
Average Price Target
$90.75
▲(22.52% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.71% Mutual Funds
0.24% Other Institutional Investors
93.11% Public Companies and Individual Investors